Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors

Ähnliche Einträge

• Considerations in the Management of Patients With Philadelphia Chromosome–Positive Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy
  von: Kantarjian, Hagop, et al.
  Veröffentlicht: (2011)
• Estimations of the Increasing Prevalence and Plateau Prevalence of Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors Therapy
  von: Huang, Xuelin, et al.
  Veröffentlicht: (2012)
• Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia
  von: Quintás-Cardama, Alfonso, et al.
  Veröffentlicht: (2009)
• Molecular Monitoring in Chronic Myeloid Leukemia: Response to Tyrosine Kinase Inhibitors and Prognostic Implications
  von: Jabbour, Elias, et al.
  Veröffentlicht: (2008)
• Long-Term Outcomes in the Second-Line Treatment of Chronic Myeloid Leukemia: A Review of Tyrosine Kinase Inhibitors
  von: Jabbour, Elias, et al.
  Veröffentlicht: (2010)